Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Despite different management strategies, progression of proteinuria occurs in a sizable category of patients with diabetic nephropathy (DN).

Vitamin D therapy is found to have an inhibitory effect on the RAS.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

This was a double-blind, randomized, placebo-controlled study.

What Was Measured

The subject headings attached to it are Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Kidney, Renin, Renin-Angiotensin System and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of postgraduate medicine), a journal based in India.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.